Canton Strategic (CNTN) vs Cue Biopharma (CUE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cue Biopharma (CUE) has outperformed Canton Strategic (CNTN) over the past year, losing 0.2% versus a loss of 25.2%. Canton Strategic is the larger company by market cap ($165.7 million vs $162.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTN | CUE |
|---|---|---|
| Share price | $2.08 | $22.33 |
| Market cap | $165.74M | $162.21M |
| 1-day change | -7.96% | -0.80% |
| YTD return | -25.41% | +146.01% |
| 1-year return | -25.17% | -0.22% |
| 5-year return | — | -94.04% |
| EPS (TTM) | $-0.10 | $-29.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.89 | $45.50 |
| 52-week low | $1.75 | $4.98 |
| Distance from 52-week high | -69.81% | -50.92% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +294.09% |
| Average volume | 751.76K | 267.68K |
| Shares outstanding | 79.68M | 7.26M |
| Employees | 12 | 29 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed CNTN by 24.9 percentage points over the past year.
- The two companies sit in different sectors: Canton Strategic in Healthcare and Cue Biopharma in Health Care.
About Canton Strategic
CNTN stock →Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States.
Healthcare · Biotechnology · 12 employees
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
CNTN vs CUE FAQ
Which is bigger, Canton Strategic or Cue Biopharma?
Canton Strategic (CNTN) is larger, with a market capitalization of $165.74M compared with $162.21M for Cue Biopharma (CUE).
Which stock has performed better over the past year, CNTN or CUE?
CUE returned -0.22% over the past 12 months, compared with -25.17% for CNTN (price return, excluding dividends). Past performance does not predict future results.
Are Canton Strategic and Cue Biopharma in the same industry?
No. Canton Strategic is in the Healthcare sector, while Cue Biopharma is in Health Care.